tbuckley/cabot-search huggingface dataset:
Ethical debate: Too drunk to care? Ethanol, emergencies, and ethical dilemmas Commentary: Guidelines could never be developed Commentary: Balance the risk as best you can Commentary: Doctors can never have a moral holiday
Authors: D. M Cressey, H. Rigter, I. de Beaufort, G. Rees, P. Walsh
Journal: BMJ (1998)

# Too drunk to care? {#article-title-2} What should doctors do if they are faced with a medical emergency after they have had a few alcoholic drinks? Dr David Cressey describes how, although not entirely sober, he felt compelled to help an unconscious person at a sports event, and two medical ethicists, a psychologist, and another doctor give their views. # Ethanol, emergencies, and ethical dilemmas {#article-title-3} While attending a recent sports event as a spectator, I was faced with a dilemma. I saw an incident in which a spectator was left unconscious and could have injured his neck. The injured man had been placed in the recovery position but was not moving. As the official crowd doctor was not immediately on hand, I felt I should at least offer my services. However, I had had an alcoholic drink. I told the attending ground steward that I was an anaesthetist, and warned him of the risks of a possible neck injury. The steward then asked for my help. I quickly assessed the patient; he had a clear airway, was breathing adequately, had a strong pulse, was pink and well perfused. None the less he had a coma score of 3, and I had seen him drinking and eating moments before the accident. When the paramedics and official crowd doctor arrived, the patient was fitted with a hard collar and was placed on a scoop stretcher. Having introduced myself to the crowd doctor and briefed him on the patient's state, I told him that I had had a drink. I then had to decide whether I should participate further in the patient's care. Here was a young man with a possible neck injury and in a hard collar. He had a full stomach, a coma score of 3, and although currently maintaining his own airway, the protective reflexes were obtunded. Immediate intubation had been considered … Correspondence to: Professor Rigter
<i>In vitro</i> diagnosis of atopic allergy in children
Authors: D. Gustafsson, D. Danielsson
Journal: Allergy (1988)

A new multi RAST (Phadiatop®) was compared with conventional RAST and total IgE determination (PRIST) for the diagnosis of IgE‐mediated allergy in children. Serum specimens were tested from 100 children with a suspected IgE‐mediated allergy, restricted to the eyes and/or the respiratory tract, to inhalant allergens. Compared with a RAST panel of 12 allergens representing seven groups, the new multi RAST showed a sensitivity of 95% and a specificity of 100% with a predictive value for positive test of 100% and for negative test of 91%. Corresponding figures for total IgE elevated &gt; 2 SD above mean determined with PRIST were 47%, 88% 84% and 56% respectively. We conclude that multi RAST might be a good adjunct to the clinical diagnosis of IgE‐mediated allergy to inhalant allergens.
Abstract 14029: Cumulative Cigarette Smoking Exposure and Heart Failure Risk in Older Adults the Health, Aging, and Body Composition (Health ABC) Study
Authors: Deepa M Gopal, Vasiliki V Georgiopoulou, Andreas P Kalogeropoulos, Andrew L Smith, Douglas C Bauer, Anne B Newman, Kirsten Bibbins-Domingo, Hillary Tindle, Tamara B Harris, Stephen B Kritchevsky, W.H. Wilson Tang, Javed Butler
Journal: Circulation (2011)

Background: The association between cumulative cigarette smoking exposure and heart failure (HF) risk in older adults has not been well characterized. Methods: We examined the association between (...
The Promise of the Americans With Disabilities Act for People With Mental Illness
Authors: Ira Burnim
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
STUDIES ON ESTIMATION OF CATALASE ACTIVITY BY THE USE OF TITANIUM SULFATE.
Authors: Shigeru Fujimoto
Journal: Cancer Research (1965)

Summary  An improved method for the determination of catalase activity is described; it is a modification of the method of Patti and Bonet-Maury (21). The new method depends on the colorimetric determination of the yellow complex formed by titanium sulfate and H2O2, and eliminates some of the complications of the titration methods previously used.
Lumbar Disc Disease
Authors: Joan Stephenson
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Investigations into the emergence of pertactin-deficient Bordetella pertussis isolates in six European countries, 1996 to 2012
Authors: A Zeddeman, M van Gent, C J Heuvelman, H G van der Heide, M J Bart, A Advani, H O Hallander, C H Wirsing von König, Marion Riffelman, J Storsaeter, D F Vestrheim, T Dalby, K A Krogfelt, N K Fry, A M Barkoff, J Mertsola, Q He, F Mooi
Journal: Eurosurveillance (2014)

Binary file ES_Abstracts_Final_ECDC.txt matches
Abstract 5: CPR Fraction Prior to Defibrillation Determines Survival in Prehospital Cardiac Arrest in the Resuscitation Outcomes Consortium (ROC) Epistry
Authors: James Christenson, Douglas Andrusiek, Siobhan P Everson-Stewart, Peter J Kudenchuk, David Hostler, Judy Powell, Clifton W Callaway, Dan Bishop, Christian Vaillancourt, Daniel P Davis, Tom P Aufderheide, Ahamed Adris, John A Stouffer, Ian Stiell
Journal: Circulation (2007)

Introduction : In 2005, the American Heart Association recommended increased “hands-on time” during cardiopulmonary resuscitation (CPR) based on animal research and small case series. This study estimated the effect of increasing CPR fraction (proportion of resuscitation time with active CPR) on survival in a cohort of patients with out-of hospital ventricular fibrillation or ventricular tachycardia (VF/VT). Methods: Patients were selected from the ROC Epistry who had a confirmed VF/VT cardiac arrest that was not witnessed by Emergency Medical Services (EMS), received no public access defibrillation shock prior to EMS arrival, and had impedance recordings of CPR before the first shock. The proportion of each minute with active CPR, from defibrillator pad application until the first shock, was measured from the electronic resuscitation record by skilled readers who were blinded to hospital discharge outcome. The effect of increasing CPR fraction on survival to hospital discharge was adjusted for age, sex, bystander CPR, public location, interval from 911 call to defibrillator activation, chest compression rate, and ROC community. Results: Of 7963 EMS-treated cases of cardiac arrest without public access defibrillation, 1893 had an initial rhythm of VF/VT and 283 of those had electronic tracings and confirmed outcome. Mean age was 63 years and 81% were male. Bystanders performed CPR on 51% and 41% arrested in a public location. Outcomes and odds ratios (OR) with 95% confidence intervals (CI) of survival are shown from lowest to highest category of CPR fraction. Conclusions: This study provides preliminary evidence that increasing CPR fraction is associated with increased survival from VF/VT cardiac arrest. Though the study was observational, relatively small, and able only to measure CPR fraction after pad application, these findings suggest that provision of minimally interrupted CPR has direct clinical impact on survival after VF cardiac arrest.
Abstract S6-01: Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1
Authors: Sara A Hurvitz, Fabrice Andre, Zefei Jiang, Zhimin Shao, Silvia P Neciosup, Max S Mano, Ling-Min Tseng, Qingyuan Zhang, Kunwei Shen, Donggeng Liu, Lydia M Dreosti, Jifeng Feng, Howard A Burris, Masakazu Toi, Marc E Buyse, David Cabaribere, Mary-Ann Lindsay, Tiffany Kunz, Shantha Rao, Lida B Pacaud, Tetiana Taran, Dennis Slamon
Journal: Cancer Research (2015)

Abstract Background: Everolimus (EVE), an inhibitor of mammalian target of rapamycin (mTOR), is a protein kinase central to a number of signaling pathways regulating cell growth and proliferation. In early studies, EVE showed antitumor activity in breast cancer and synergy with both trastuzumab (TRAS) and paclitaxel. The international BOLERO-1 study is being conducted to evaluate the addition of EVE to TRAS plus paclitaxel as first-line therapy for HER2+ advanced breast cancer. Methods: In this phase 3 randomized trial, 719 adult women with HER2+ advanced breast cancer who had not received prior TRAS or chemotherapy in the advanced setting were randomized 2:1 to receive either EVE or placebo (10 mg) in combination with weekly paclitaxel and TRAS. The two primary objectives were to compare the progression-free survivals (PFS) of everolimus/trastuzumab/paclitaxel and trastuzumab/paclitaxel/placebo in both the full population and in the Hormone Receptor negative (HR-) subpopulation. Secondary endpoints included survival, response rate, and safety. The final analysis was performed after 420 PFS events were observed in the full population. Results: In the full population, the median age was 53 years, 70.4% had visceral metastases, 56.1% had ER and/or PgR +ve disease, and 43.3% had ≥ 3 metastatic sites. Previous adjuvant therapy included TRAS (11.4%) and taxane (24.7%). Conclusions: The data from the final analysis will be available in October 2014. PFS, safety, and secondary efficacy endpoints will be presented at SABCS 2014. (Funded by Novartis; BOLERO-1 ClinicalTrials.gov number, NCT00876395.) Citation Format: Sara A Hurvitz, Fabrice Andre, Zefei Jiang, Zhimin Shao, Silvia P Neciosup, Max S Mano, Ling-Min Tseng, Qingyuan Zhang, Kunwei Shen, Donggeng Liu, Lydia M Dreosti, Jifeng Feng, Howard A Burris, Masakazu Toi, Marc E Buyse, David Cabaribere, Mary-Ann Lindsay, Tiffany Kunz, Shantha Rao, Lida B Pacaud, Tetiana Taran, Dennis Slamon. Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1 [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr S6-01.
Enoxaparin vs Unfractionated Heparin in Acute Coronary Syndrome
Authors: Michael Pedrini, Frank Hartig, Christoph Pechlaner
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
992. Lentiviral and Retroviral Vectors for Transcriptionally Targeted Expression of Human Beta-Globin
Authors: Duncan McVey, Chi Hsu, Lisa Wei, C. Richter King, Douglas E. Brough
Journal: Molecular Therapy (2004)

Top of pageAbstract
Transgene expression driven by the human cytomegalovirus (hCMV) promoter from adenovectors following intravitreal administration into the eye is characterized by an initial high-level burst of expression that drops quickly and is followed by eventual loss of transgene expression. The decrease in expression could arise from elimination of vector genomes or by loss of promoter activity. In the current studies we investigate the cause for the diminution of activity, evaluate quantitatively vector genomes and expression levels, describe a means in which to follow transgene expression in the eye in the same animal over time, and discover means in which silenced adenovector genomes can be reactivated to express transgenes. In these studies, replication-deficient adenovectors deleted of E1, E3 and E4 that express nothing, GFP, or luciferase from the hCMV promoter were delivered to the eyes of mice by direct intravitreal injection. The amount of vector genome was quantitated by qPCR, the amount of luciferase transgene expression quantitated by luminesence, and the level of GFP transgene expression monitored by fluorescence. From these analyses the loss of transgene expression over time from adenovectors can be attributed to loss of promoter activity. Adenovector genomes from which there was no detectable transgene expression still retained the ability to express their protein product. This was shown by the ability to completely restore expression from a silenced hCMV promoter by multiple means. The administration of non-expressing adenovector particles to the vitreous activated expression from the silenced adenovector genome to levels equal to or greater than that originally observed on day 1. These experiments also showed that quiescent adenovector genomes retain the ability to be reactivated for transgene expression even after being silenced for more than a year. A screen of potential molecules capable of activating the hCMV promoter found retinoic acid (RA) to be a potent activator of expression and systemic administration of RA was found to activate expression from silenced adenovector genomes to day 1 levels. Furthermore, we found that RA could activate expression from silenced adenovector genomes even after 2 months following initial administration into the eye, which further demonstrates that adenovector genomes remain expression competent. These data suggest that adenovectors may provide a means to deliver proteins to the eye requiring repeated expression for the treatment of ocular disease and expands the utility of adenovectors in ocular gene delivery.
Changes in basophil activation during grass-pollen sublingual immunotherapy do not correlate with clinical efficacy
Authors: L. Van Overtvelt, V. Baron-Bodo, S. Horiot, H. Moussu, C. Ricarte, F. Horak, P. Zieglmayer, R. Zieglmayer, A. Montagut, S. Galvain, O. de Beaumont, M. Le Gall, P. Moingeon
Journal: Allergy (2011)

Biomarkers predicting the safety and efficacy of sublingual immunotherapy (SLIT) remain to be established.Eighty-nine patients with allergic rhinoconjunctivitis to grass pollen received either a placebo or five-grass-pollen daily tablet sublingually for 4 months. Following exposure in an allergen challenge chamber, clinical responders and nonresponders were identified individually by evaluating their rhinoconjunctivitis total symptom score (RTSS). Activation of peripheral blood basophils was measured by cytofluorometry before and after 2 or 4 months of immunotherapy, based on CD203c surface expression following allergen stimulation.Patients receiving the grass-pollen tablet had a relative mean improvement of 29.3% vs placebo in the average RTSS after 4 months of SLIT (P < 0.0003). No significant changes in basophil activation were noticed after 2 or 4 months of SLIT despite induction of specific IgGs. Among individual clinical responders, basophil activation was either decreased, increased, or unmodified during SLIT. Levels of basophil activation prior to immunotherapy were not predictive of local adverse reactions associated with immunotherapy. A moderate association was found between basophil activation and allergen-specific IgE levels, skin reactivity, or RTSS, suggesting that the former is, to some extent, indicative of disease severity. As such, patients with the highest level of basophil activation before treatment were more likely to benefit clinically from SLIT.Allergen reactivity of peripheral blood basophils is not a biomarker for adverse events or early onset of clinical responses to SLIT.
PENICILLIN TREATMENT OF SULFA-RESISTANT GONORRHEA; RESULTS OF 500 CASES TREATED WITH 50,000 UNITS OF PENICILLIN
Authors: Allen I. Josey, Forrest E. Kirshman
Journal: Annals of Internal Medicine (1945)

Article1 June 1945PENICILLIN TREATMENT OF SULFA-RESISTANT GONORRHEA; RESULTS OF 500 CASES TREATED WITH 50,000 UNITS OF PENICILLINALLEN I. JOSEY, FORREST E. KIRSHMANALLEN I. JOSEYSearch for more papers by this author, FORREST E. KIRSHMANSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-22-6-807 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptDuring the early observation of the effects of penicillin on various organisms the gonococcus was found to be susceptible, and during 1943 its successful use in several small series of cases was reported.1, 2, 3Recently Ferguson and Buckholtz,4in reporting the results of treatment in 735 cases of sulfonamide resistant gonorrhea with varying doses of penicillin, indicated that a dosage of at least 100,000 Oxford units was necessary for uniformly satisfactory results. During the summer of 1943 O'Reilly General Hospital, among a number of other general hospitals, was assigned the task of treating several groups of sulfa-resistant gonorrhea with...Bibliography1. RICHARDS AN: Penicillin—Statement Released by Committee on Medical Research, Jr. Am. Med. Assoc., 1943, cxxii, 235. Google Scholar2. HERRELLCOOKTHOMPSON WEENL: Use of penicillin in sulfonamide resistant gonorrheal infections, Jr. Am. Med. Assoc., 1943, cxxii, 289. CrossrefGoogle Scholar3. Keefer CS Blake FG Marshall EK Lockwood JS Wood WB Penicillin in the Treatment of Infections: Statement by the Committee on Chemotherapeutic and Other Agents, Division of Medical Sciences, National Research Council, , Boston, Chairman; , New Haven, Conn.; , Baltimore; , Philadelphia and , St. Louis, Jr. Am. Med. Assoc., 1943, cxxii, 1217. CrossrefGoogle Scholar4. FERGUSONBUCKHOLTZ CM: Penicillin therapy of gonorrhea in men, Jr. Am. Med. Assoc., 1944, cxxv, 23. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Received for publication August 29, 1944.From the Medical Service, O'Reilly General Hospital. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byTHERAPY OF GONOCOCCAL ARTHRITIS*PAUL O. HAGEMANN, M.D., F.A.C.P., AARON HENDIN, M.D., HAROLD H. LURIE, M.D., MARVIN STEIN, M.D. 1 June 1945Volume 22, Issue 6Page: 807-810KeywordsGonorrheaMedical servicesNeisseria gonorrhoeaePenicillinSulfonamide ePublished: 1 December 2008 Issue Published: 1 June 1945 PDF downloadLoading ...
Comparison of the Virulence of the Mammary-Tumor Agent From Four Strains of Mice&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Hummel, Katharine P., Little, C. C.
Journal: JNCI Journal of the National Cancer Institute (1959)

Journal Article Comparison of the Virulence of the Mammary-Tumor Agent From Four Strains of Mice Get access Katharine P. Hummel, Ph.D., Katharine P. Hummel, Ph.D. Roscoe B. Jackson Memorial Laboratory, Bar Harbor, Maine Search for other works by this author on: Oxford Academic PubMed Google Scholar C. C. Little, Sc.D C. C. Little, Sc.D Roscoe B. Jackson Memorial Laboratory, Bar Harbor, Maine Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 23, Issue 4, October 1959, Pages 813–821, https://doi.org/10.1093/jnci/23.4.813 Published: 01 October 1959 Article history Received: 02 April 1959 Published: 01 October 1959
The Green Bridge II
Authors: M. Therese Southgate
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal